This technology is a monoclonal antibody therapy targeting human Annexin A1 that specifically inhibits cancer growth and protects healthy tissue.
Traditional cancer chemotherapy is toxic to patients due to off-target effects and limited in efficacy due to the outgrowth of chemo-resistant cancer cells. There is a need for cancer therapies that target molecules specifically expressed by malignant tumor cells and can combat mechanisms of acquired chemo-resistance.
This technology limits tumor growth by targeting Annexin A1 (ANXA1) with a human monoclonal antibody (mAb). Outgrowth of the gut microbe, F. nucleatum, upregulates ANXA1 in proliferating colorectal cancer cells, and signaling through ANXA1 drives oncogene expression, inflammation, and chemo-resistance. Targeting ANXA1 with this mAb reduces ANXA1 expression in cancer cells, limiting tumor growth and sensitizing colorectal cancer cells to chemotherapeutics. As ANXA1 expression is exclusively present within proliferative cancer cells, this technology offers therapeutic efficacy while protecting healthy tissue.
This technology has been validated in vitro and in xenograft mouse models of colorectal cancer.
Patent Issued (US 11,952,416)
IR CU21239, CU21243, CU21244
Licensing Contact: Jerry Kokoshka